Published in Oncol Rev on October 05, 2012
Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett (2015) 0.90
PDZ domains and viral infection: versatile potentials of HPV-PDZ interactions in relation to malignancy. Biomed Res Int (2013) 0.86
Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma. Virol J (2017) 0.75
Association of P73 polymorphisms with susceptibilities of cervical carcinoma: a meta-analysis. Oncotarget (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Innate immune recognition. Annu Rev Immunol (2001) 26.65
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
Signaling to NF-kappaB. Genes Dev (2004) 19.78
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A (1983) 14.73
Classification of papillomaviruses. Virology (2004) 14.16
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 12.41
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J (1984) 10.28
Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta (1996) 7.79
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J (1989) 7.69
Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61
The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell (1988) 6.28
Innate recognition of viruses. Immunity (2007) 6.21
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. EMBO J (1991) 6.00
Carcinogenicity of human papillomaviruses. Lancet Oncol (2005) 5.84
Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 5.76
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst (2000) 5.32
The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 5.21
Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science (1990) 4.92
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol (2009) 4.61
Molecular cloning of viral DNA from human genital warts. J Virol (1981) 4.50
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med (1999) 4.40
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Natural killer cells, viruses and cancer. Nat Rev Immunol (2001) 4.21
Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol (2008) 4.17
Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol (2008) 4.16
E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res (1996) 4.14
Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev (1998) 4.06
Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int J Cancer (1980) 4.03
Mechanisms of human papillomavirus-induced oncogenesis. J Virol (2004) 3.95
NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 3.86
The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region. EMBO J (1987) 3.86
Antiviral signaling through pattern recognition receptors. J Biochem (2006) 3.84
Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc Natl Acad Sci U S A (1992) 3.58
Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol (2009) 3.51
The papillomavirus life cycle. J Clin Virol (2005) 3.41
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol (1993) 2.91
Human papillomaviruses. Annu Rev Microbiol (1994) 2.88
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev (1997) 2.65
NF-κB in immunobiology. Cell Res (2011) 2.61
NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ (2006) 2.59
The IkappaB kinase - a bridge between inflammation and cancer. Cell Res (2008) 2.52
Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev (2010) 2.44
Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J Exp Med (2002) 2.37
Recognition of viral nucleic acids in innate immunity. Rev Med Virol (2010) 2.33
Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology (1997) 2.29
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22
Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res (1999) 2.17
The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene (1999) 2.11
Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature (1991) 2.09
Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol (2011) 2.01
The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J Virol (1994) 2.01
Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene (2008) 1.93
Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer (2002) 1.92
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90
Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene (1996) 1.83
Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J Virol (1997) 1.82
Pattern recognition receptors and the innate immune response to viral infection. Viruses (2011) 1.82
The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis (1993) 1.78
Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol (2009) 1.77
Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene (2008) 1.69
Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol (2007) 1.65
Insights into Langerhans cell function from Langerhans cell ablation models. Eur J Immunol (2008) 1.65
Modulation of NF-κB signalling by microbial pathogens. Nat Rev Microbiol (2011) 1.64
Innate immune response to viral infection. Cytokine (2008) 1.63
Pathology and epidemiology of HPV infection in females. Gynecol Oncol (2010) 1.62
Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J Virol (1991) 1.62
The role of the E1 and E2 proteins in the replication of human papillomavirus type 31b. Virology (1994) 1.61
Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene (2003) 1.59
Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem (2000) 1.52
Immune evasion of natural killer cells by viruses. Curr Opin Immunol (2008) 1.51
Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis (2000) 1.50
The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol (2005) 1.48
VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci (2003) 1.46
Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (2003) 1.45
The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene (1999) 1.44
Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ (1997) 1.43
Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions. J Virol (1998) 1.40
HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene (1993) 1.40
Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium. Virology (1998) 1.30
Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res (1997) 1.29
Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int J Cancer (2006) 1.27
Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets (2007) 1.26
Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol (2006) 1.25
A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer (2010) 1.25
Viral evasion of T cell immunity: ancient mechanisms offering new applications. Curr Opin Immunol (2010) 1.24